KPV is a tripeptide: lysine-proline-valine. Those three residues are the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), corresponding to amino acids 11 through 13. Researchers became interested in it for a simple reason. The anti-inflammatory activity of alpha-MSH largely survives when you cut the molecule down to this fragment, while the pigmentation and other hormonal effects of the full peptide do not. That makes KPV a stripped-down tool for studying inflammation.
It is a small, defined molecule (formula C16H30N4O4, molar mass about 342 g/mol), not a proprietary drug.
What the research shows
Most of the published work is preclinical, and the strongest line of it concerns the gut.
The most-cited study is from Dalmasso and colleagues in Gastroenterology (2008). They reported that KPV is taken up into intestinal epithelial cells and immune cells through PepT1, a transporter for di- and tripeptides. Once inside, nanomolar concentrations blunted activation of the NF-kappaB and MAP kinase signaling pathways and cut secretion of pro-inflammatory cytokines. Given orally to mice, KPV reduced the severity of chemically induced (DSS and TNBS) colitis. See the PubMed record.
A second 2008 paper, by Kannengiesser and colleagues in Inflammatory Bowel Diseases, tested KPV across several mouse colitis models. Treated animals recovered weight faster and had less inflammatory infiltrate. Notably, the effect held even in mice with a nonfunctional melanocortin-1 receptor, which led the authors to conclude that KPV's action is at least partly independent of MC1R (PubMed). So there appear to be at least two routes by which it can act: classic melanocortin-receptor signaling, and a receptor-independent intracellular effect.
There is also older work on the parent fragment. Cutuli and colleagues, writing in the Journal of Leukocyte Biology (2000), found that alpha-MSH peptides containing the C-terminal KPV sequence inhibited Staphylococcus aureus and the yeast Candida albicans in culture (PubMed). That antimicrobial signal is interesting but, again, from cell-based and microbial assays.
The honest limits
Everything above is animal or cell-culture data. As of mid-2026 there are no completed human clinical trials of KPV for inflammatory bowel disease, wound healing, skin inflammation, or any other use, and no registered trials of note. KPV is not approved by the FDA or any comparable regulator for human use. The U.S. FDA's compounding advisory committee has KPV on a 2026 agenda to consider whether it belongs on a bulk-substances list for pharmacy compounding, which is a regulatory review, not an approval.
Because it is unapproved, KPV sold to the public is research-use-only material. Nothing here is medical, dosing, or treatment advice.
The buyer's angle: identity and purity
KPV is a short, achiral-to-synthesize peptide, but "short and simple" does not guarantee what is in the vial. For a research-only compound with no pharmaceutical oversight, third-party documentation is the only check a buyer has. The things worth looking for on a certificate of analysis are identity (mass spec confirming the Lys-Pro-Val sequence and the ~342 Da mass), purity by HPLC, and tests for residual solvents and endotoxin. peptideone aggregates independent vendor ratings and testing signals rather than running its own assays; treat any vendor purity claim as a claim until a COA from an independent lab backs it.